Epsilon M&A Deal Report - Heidelberg Pharma
Transaction Multiples for the Valuation of Private Companies
Wilex / Heidelberg Pharma
No EMAT :
21959
Announced Date :
03/11/2010
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Wilex
Target :
Heidelberg Pharma
Country :
Germany
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
Business Description :
Heidelberg Pharma AG is a drug development company focused on cancer. > The company has two business units: The first comprises a novel conjugate platform technology for therapeutic antibodies...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
ns |
|
|||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 43
| Date | Acquirer | Target | Country | Multiples | See details |
| 01/12/2010 | Dechra Pharmaceuticals | Genitrix | United Kingdom | * | 21955 |
| 12/03/2007 | Smith & Nephew (S&N) | Plus Orthopedics Holding | Switzerland | *** | 21950 |
Source: Epsilon Research / EMAT
